Koriakin V A, Zeliger L R, Galenko N N
Probl Tuberk. 1991(9):38-40.
The effectiveness of tarivid, a new drug having a broad spectrum of antimicrobial action and antituberculous effect, was studied. The drug was given to 29 patients with newly detected destructive pulmonary tuberculosis and bacillary excretion. Eight patients had microbacterial resistance to streptomycin, rifampicin and isoniazid, 12 had tolerance to them, in 9 patients tuberculosis was complicated by a nonspecific inflammatory process. The course of treatment ranged from 3 weeks to 3 months. The drug was well tolerated. Its effect was manifested by reduction of intoxication, resolution of the inflammatory and pericavitary pulmonary lesions and bacilli absence. Tarivid can be considered an efficacious drug in the multimodality therapy of tuberculosis patients.
对一种具有广谱抗菌作用和抗结核效果的新药泰利必妥的疗效进行了研究。该药物用于29例新发现的有肺部破坏性病变且有结核菌排出的患者。8例患者对链霉素、利福平及异烟肼有细菌耐药性，12例患者对这些药物耐受，9例患者的结核病并发了非特异性炎症过程。治疗疗程从3周持续至3个月。该药物耐受性良好。其效果表现为中毒症状减轻、肺部炎症和空洞周围病变消退以及细菌消失。泰利必妥可被认为是结核病患者多模式治疗中的一种有效药物。
